GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Total Equity

Relmada Therapeutics (STU:4E2) Total Equity : €57.13 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Total Equity?

Relmada Therapeutics's total equity for the quarter that ended in Jun. 2024 was €57.13 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Relmada Therapeutics Total Equity Historical Data

The historical data trend for Relmada Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Total Equity Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.74 86.79 184.32 132.57 78.27

Relmada Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.76 94.38 78.27 66.28 57.13

Relmada Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Relmada Therapeutics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=89.455-11.183
=78.27

Relmada Therapeutics's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=65.985-8.86
=57.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Total Equity
Comparable Companies
HOWL MIRO ALDX NYMXF HRTX ADVM OCGN NKTR SGMO BDTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RLMD:USA
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Website
https://www.relmada.com
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines